Xiaolin Wang - Mar 1, 2024 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
Officer
Signature
/s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang
Stock symbol
RVMD
Transactions as of
Mar 1, 2024
Transactions value $
$0
Form type
4
Date filed
3/5/2024, 04:52 PM
Previous filing
Mar 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Award $0 +24.2K +40.12% $0.00 84.5K Mar 1, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Award $0 +84.7K $0.00 84.7K Mar 1, 2024 Common Stock 84.7K $29.80 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 62,513 restricted stock units.
F2 Includes 1,513 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2023.
F3 One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.